bluebird bio Inc BLUE:NASDAQ

Last Price$10.42Cboe Real-Time Last Sale as of 1:39PM ET 12/01/21
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.31(3.07%)
Bid (Size)$10.41 (104)
Ask (Size)$10.45 (500)
Day Low / High$10.10 - 10.77
Volume614.5 K

View Biotechnology IndustryPeer Comparison as of 12/01/2021


bluebird bio Inc ( NASDAQ )

Price: $10.42
Change: +0.31 (3.07%)
Volume: 614.5 K
1:39PM ET 12/01/2021

Cara Therapeutics Inc ( NASDAQ )

Price: $12.81
Change: -0.37 (2.81%)
Volume: 236.3 K
1:39PM ET 12/01/2021

Lexicon Pharmaceuticals Inc ( NASDAQ )

Price: $4.72
Change: +0.14 (3.17%)
Volume: 285.6 K
1:37PM ET 12/01/2021

Kezar Life Sciences Inc ( NASDAQ )

Price: $14.70
Change: +0.84 (6.06%)
Volume: 1.5 M
1:39PM ET 12/01/2021

BioXcel Therapeutics Inc ( NASDAQ )

Price: $20.58
Change: -2.35 (10.25%)
Volume: 669.6 K
1:39PM ET 12/01/2021

Read more news Recent News

Bluebird bio's Blood Disorder Therapy Biologics License Application Accepted for FDA Priority Review; Shares Rise Pre-Bell
6:58AM ET 11/22/2021 MT Newswires

Bluebird bio (BLUE) said Monday the US Food and Drug Administration has accepted for priority review the company's biologics license application for...

--Berenberg Bank Adjusts Bluebird Bio's Price Target to $11 From $21, Maintains Hold Rating
7:10AM ET 11/12/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Bluebird bio Shares Sink Following Downgrades From Analysts After Spin-off
2:45PM ET 11/08/2021 MT Newswires

Bluebird bio (BLUE) shares were down over 18% after the company was downgraded by a bunch of analysts following the completion of its 2seventy bio spinoff....

--Barclays Adjusts bluebird bio's Price Target to $13 from $20, Keeps Equalweight Rating
1:20PM ET 11/08/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

View all Commentary and Analysis

Wall Street Breakfast: What Moved Markets
8:01AM ET 11/06/2021 Seeking Alpha

bluebird bio: Waiting For The Dust To Settle
3:43AM ET 11/03/2021 Seeking Alpha

bluebird bio: Like A Bird In The Middle Of The Deep Blue Sea
9:30PM ET 11/02/2021 Seeking Alpha

MaxCyte: Enabling Next-Generation Cell Based Therapies, Attractive Risk-Return Profile
1:28PM ET 9/06/2021 Seeking Alpha

Company Profile

Business Descriptionbluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA. View company web site for more details
Address60 Binney Street
Cambridge, Massachusetts 02142
Number of Employees764
Recent SEC Filing11/23/20218-K
DirectorNick Leschly
President, Chief Executive Officer & DirectorAndrew Obenshain
Chief Financial OfficerGina R. Consylman
Secretary, Senior Vice President & General CounselHelen C. Fu

Company Highlights

Price Open$10.22
Previous Close$10.11
52 Week Range$9.89 - 53.68
Market Capitalization$730.5 M
Shares Outstanding70.1 M
SectorHealth Technology
Next Earnings Announcement02/22/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$12.34
Beta vs. S&P 500N/A
Revenue$54.6 M
Net Profit Margin-1,610.78%
Return on Equity-78.38%

Analyst Ratings as of 11/18/2021

Consensus RecommendationConsensus Icon
Powered by Factset